Andrographolide attenuates synovial inflammation of osteoarthritis by interacting with tumor necrosis factor receptor 2 trafficking in a rat model.

Andrographolide NF-κB OA treatment Synovial inflammation TNFR2 trafficking

Journal

Journal of orthopaedic translation
ISSN: 2214-031X
Titre abrégé: J Orthop Translat
Pays: Singapore
ID NLM: 101625127

Informations de publication

Date de publication:
Jul 2021
Historique:
received: 18 01 2021
revised: 28 04 2021
accepted: 03 05 2021
entrez: 7 6 2021
pubmed: 8 6 2021
medline: 8 6 2021
Statut: epublish

Résumé

Synovial inflammation plays a major role in the pathogenesis of osteoarthritis (OA). This study investigated the effect of andrographolide (Andro) on synovial inflammation mediated by tumor necrosis factor-alpha receptor 2 (TNFR2) trafficking and its utility in attenuating OA progression. Knee joints were harvested from rats subjected to radial transection of the medial collateral ligament (MCLT) and medial meniscus (MMT) to examine the effect of Andro on synovial inflammation and OA progression. Quantitative real-time polymerase chain reaction was used to evaluate the expression of inflammatory factors in primary fibroblast-like synoviocytes (FLSs) after Andro treatment Andro treatment was found to reduce synovial inflammation and OA progression Andro could suppress synovial inflammation via regulation of TNFR2 trafficking and degradation. This also suggests it could be a potential treatment for the prevention of synovial inflammation and OA progression. This study provides strong evidence that Andro reduces NF-κB activation and inflammatory responses in OA FLSs via regulation of TNFR2 trafficking. The inhibition of TNFR2 and Andro could be a novel therapeutic approach for OA and pain management.

Sections du résumé

BACKGROUND BACKGROUND
Synovial inflammation plays a major role in the pathogenesis of osteoarthritis (OA). This study investigated the effect of andrographolide (Andro) on synovial inflammation mediated by tumor necrosis factor-alpha receptor 2 (TNFR2) trafficking and its utility in attenuating OA progression.
METHODS METHODS
Knee joints were harvested from rats subjected to radial transection of the medial collateral ligament (MCLT) and medial meniscus (MMT) to examine the effect of Andro on synovial inflammation and OA progression. Quantitative real-time polymerase chain reaction was used to evaluate the expression of inflammatory factors in primary fibroblast-like synoviocytes (FLSs) after Andro treatment
RESULTS RESULTS
Andro treatment was found to reduce synovial inflammation and OA progression
CONCLUSIONS CONCLUSIONS
Andro could suppress synovial inflammation via regulation of TNFR2 trafficking and degradation. This also suggests it could be a potential treatment for the prevention of synovial inflammation and OA progression.
THE TRANSLATIONAL POTENTIAL OF THIS ARTICLE UNASSIGNED
This study provides strong evidence that Andro reduces NF-κB activation and inflammatory responses in OA FLSs via regulation of TNFR2 trafficking. The inhibition of TNFR2 and Andro could be a novel therapeutic approach for OA and pain management.

Identifiants

DOI: 10.1016/j.jot.2021.05.001 PMID: 34094861 PMC: PMC8144533
pubmed: 34094861
doi: 10.1016/j.jot.2021.05.001
pii: S2214-031X(21)00032-2
pmc: PMC8144533
doi:

Types de publication

Journal Article

Langues

eng

Pagination

89-99

Informations de copyright

© 2021 Published by Elsevier (Singapore) Pte Ltd on behalf of Chinese Speaking Orthopaedic Society.

Déclaration de conflit d'intérêts

The authors have declared no conflicts of interest.

Références

Expert Opin Ther Targets. 2019 Apr;23(4):295-307
pubmed: 30856027
J Biol Chem. 2000 May 12;275(19):14608-14
pubmed: 10799547
Biochem Pharmacol. 2016 Sep 1;115:94-103
pubmed: 27265145
Ann Rheum Dis. 2017 May;76(5):914-922
pubmed: 27965260
Arthritis Res Ther. 2015 Oct 14;17:287
pubmed: 26462474
J Headache Pain. 2019 Jan 31;20(1):11
pubmed: 30704400
Cell Signal. 2011 Jan;23(1):161-70
pubmed: 20807567
J Cell Biochem. 2011 Dec;112(12):3507-14
pubmed: 21815191
Matrix Biol. 2016 Dec;56:57-73
pubmed: 27084377
Int J Mol Sci. 2017 Dec 08;18(12):
pubmed: 29292760
Osteoarthritis Cartilage. 2010 Oct;18 Suppl 3:S24-34
pubmed: 20864021
Osteoarthritis Cartilage. 2013 Sep;21(9):1355-64
pubmed: 23973150
Ann Rheum Dis. 2015 Jan;74(1):242-51
pubmed: 24130267
Mol Pain. 2016 Nov 15;12:
pubmed: 27852966
Ann N Y Acad Sci. 2002 Jun;966:343-54
pubmed: 12114291
Osteoarthritis Cartilage. 2019 Nov;27(11):1578-1589
pubmed: 31278997
Oncogene. 2014 May 8;33(19):2520-30
pubmed: 23770847
Mod Rheumatol. 2013 Nov;23(6):1124-32
pubmed: 23242626
J Cell Sci. 2005 Aug 1;118(Pt 15):3339-51
pubmed: 16079278
Eur Cytokine Netw. 2018 Mar 1;29(1):27-35
pubmed: 29748156
Osteoarthritis Cartilage. 2017 Mar;25(3):406-412
pubmed: 27746376
Cell Death Dis. 2019 Dec 20;10(12):957
pubmed: 31862870
Pain. 2020 Sep 1;161(9):2129-2141
pubmed: 32332252
J Rheumatol. 1994 May;21(5):883-9
pubmed: 7520500
Cell Mol Immunol. 2004 Oct;1(5):373-7
pubmed: 16285897
Arterioscler Thromb Vasc Biol. 2010 Mar;30(3):395-402
pubmed: 20139367
Acta Pharmacol Sin. 2021 Apr 8;:
pubmed: 33833406
Trends Cell Biol. 2003 Mar;13(3):137-45
pubmed: 12628346
Nat Rev Mol Cell Biol. 2008 Aug;9(8):655-62
pubmed: 18545270
Life Sci. 2015 Sep 1;136:67-72
pubmed: 26141990
Ann Rheum Dis. 2011 Jul;70(7):1296-303
pubmed: 21482536
Nat Rev Rheumatol. 2012 Nov;8(11):665-73
pubmed: 22868925
Biochem Pharmacol. 2017 Sep 1;139:71-81
pubmed: 28377280
Arthritis Rheum. 2001 Jun;44(6):1237-47
pubmed: 11407681
Arthritis Rheum. 1992 Oct;35(10):1170-8
pubmed: 1329775
Am J Respir Crit Care Med. 2009 Apr 15;179(8):657-65
pubmed: 19201922
Arthritis Res Ther. 2017 Feb 2;19(1):18
pubmed: 28148295
Oxid Med Cell Longev. 2020 Sep 28;2020:7517219
pubmed: 33062145
Arthritis Rheumatol. 2014 Nov;66(11):3018-27
pubmed: 25049144
Eur J Pain. 2014 Nov;18(10):1367-75
pubmed: 24700605
Immunol Lett. 2002 Sep 2;83(2):85-93
pubmed: 12067756
Eur J Cell Biol. 2011 Jun-Jul;90(6-7):467-75
pubmed: 21144616
Nat Rev Mol Cell Biol. 2005 Feb;6(2):112-26
pubmed: 15687999
Osteoarthritis Cartilage. 2016 Feb;24(2):299-306
pubmed: 26410555
Biomaterials. 2018 Nov;183:93-101
pubmed: 30149233
Nat Rev Rheumatol. 2015 Jan;11(1):35-44
pubmed: 25266449
Eur J Med Chem. 2019 Jul 15;174:33-44
pubmed: 31022551
Arthritis Rheum. 2011 Jun;63(6):1591-602
pubmed: 21337539
J Cell Physiol. 2018 Jan;234(1):561-571
pubmed: 30071128
Neuropharmacology. 2018 Oct;141:305-315
pubmed: 30218674
Osteoarthritis Cartilage. 2006 Oct;14(10):1041-8
pubmed: 16769229
Biochem Pharmacol. 2018 Jul;153:292-298
pubmed: 29378181
Autophagy. 2014 Jun;10(6):972-85
pubmed: 24879148
Bone. 2016 Apr;85:81-90
pubmed: 26812612
Nat Rev Rheumatol. 2010 Nov;6(11):625-35
pubmed: 20924410
Osteoarthritis Cartilage. 2018 Dec;26(12):1609-1618
pubmed: 30240937
Clin Orthop Relat Res. 2000 Jul;(376):172-82
pubmed: 10906873
Br J Pharmacol. 2010 Apr;159(7):1497-510
pubmed: 20233216

Auteurs

Rongliang Wang (R)

State Key Laboratory of Pharmaceutical Biotechnology, Department of Sports Medicine and Adult Reconstructive Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu, PR China.
Joint Research Center for Bone and Joint Disease, Model Animal Research Center (MARC), Nanjing University, Nanjing, Jiangsu, 210093, PR China.

Jiawei Li (J)

State Key Laboratory of Pharmaceutical Biotechnology, Department of Sports Medicine and Adult Reconstructive Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu, PR China.
Joint Research Center for Bone and Joint Disease, Model Animal Research Center (MARC), Nanjing University, Nanjing, Jiangsu, 210093, PR China.

Xingquan Xu (X)

State Key Laboratory of Pharmaceutical Biotechnology, Department of Sports Medicine and Adult Reconstructive Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu, PR China.
Joint Research Center for Bone and Joint Disease, Model Animal Research Center (MARC), Nanjing University, Nanjing, Jiangsu, 210093, PR China.

Jia Xu (J)

Joint Research Center for Bone and Joint Disease, Model Animal Research Center (MARC), Nanjing University, Nanjing, Jiangsu, 210093, PR China.
Drum Tower of Clinical Medicine, Nanjing Medical University, Nanjing, 210008, Jiangsu, PR China.

Huiming Jiang (H)

Joint Research Center for Bone and Joint Disease, Model Animal Research Center (MARC), Nanjing University, Nanjing, Jiangsu, 210093, PR China.
Department of Sports Medicine and Joint Surgery, The Affiliated Nanjing Hospital of Nanjing Medical University, Nanjing, 210000, PR China.

Zhongyang Lv (Z)

State Key Laboratory of Pharmaceutical Biotechnology, Department of Sports Medicine and Adult Reconstructive Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu, PR China.
Joint Research Center for Bone and Joint Disease, Model Animal Research Center (MARC), Nanjing University, Nanjing, Jiangsu, 210093, PR China.

Rui Wu (R)

State Key Laboratory of Pharmaceutical Biotechnology, Department of Sports Medicine and Adult Reconstructive Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu, PR China.
Joint Research Center for Bone and Joint Disease, Model Animal Research Center (MARC), Nanjing University, Nanjing, Jiangsu, 210093, PR China.

Ziying Sun (Z)

State Key Laboratory of Pharmaceutical Biotechnology, Department of Sports Medicine and Adult Reconstructive Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu, PR China.
Joint Research Center for Bone and Joint Disease, Model Animal Research Center (MARC), Nanjing University, Nanjing, Jiangsu, 210093, PR China.

Wenjie Guo (W)

State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, 210093, PR China.

Yang Sun (Y)

State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, 210093, PR China.

Shiro Ikegawa (S)

State Key Laboratory of Pharmaceutical Biotechnology, Department of Sports Medicine and Adult Reconstructive Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu, PR China.
Laboratory for Bone and Joint Diseases, RIKEN Center for Integrative Medical Science (IMS, RIKEN), Tokyo, 108-8639, Japan.

Qing Jiang (Q)

State Key Laboratory of Pharmaceutical Biotechnology, Department of Sports Medicine and Adult Reconstructive Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu, PR China.
Joint Research Center for Bone and Joint Disease, Model Animal Research Center (MARC), Nanjing University, Nanjing, Jiangsu, 210093, PR China.
Drum Tower of Clinical Medicine, Nanjing Medical University, Nanjing, 210008, Jiangsu, PR China.
Department of Sports Medicine and Joint Surgery, The Affiliated Nanjing Hospital of Nanjing Medical University, Nanjing, 210000, PR China.

Dongquan Shi (D)

State Key Laboratory of Pharmaceutical Biotechnology, Department of Sports Medicine and Adult Reconstructive Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu, PR China.
Joint Research Center for Bone and Joint Disease, Model Animal Research Center (MARC), Nanjing University, Nanjing, Jiangsu, 210093, PR China.
Drum Tower of Clinical Medicine, Nanjing Medical University, Nanjing, 210008, Jiangsu, PR China.
Department of Sports Medicine and Joint Surgery, The Affiliated Nanjing Hospital of Nanjing Medical University, Nanjing, 210000, PR China.

Classifications MeSH